Ticagrelor's antiplatelet efficacy is partly driven by inverse agonism at the P2Y12 receptor and ENT1 transporter blockade on platelets.
Answers are grounded in this paper and cite their sources.
May underlie ticagrelor effects beyond P2Y12 blockade; leaves open clinical relevance.
Key Points Ticagrelor acts as an inverse agonist at the P2Y12R, inhibiting basal agonist-independent signaling. Ticagrelor inhibits the adenosine transporter ENT1 not only on erythrocytes, but on platelets too.
No takes yet. Share an insight, caveat, or question.
Aungraheeta et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: